Rabeprazole Sodium
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Gastric Low-grade MALT Lymphoma With Helicobacter Pylori Positive
Conditions
Gastric Low-grade MALT Lymphoma With Helicobacter Pylori Positive
Trial Timeline
Jan 13, 2011 → Nov 17, 2016
NCT ID
NCT01264822About Rabeprazole Sodium
Rabeprazole Sodium is a pre-clinical stage product being developed by Eisai for Gastric Low-grade MALT Lymphoma With Helicobacter Pylori Positive. The current trial status is completed. This product is registered under clinical trial identifier NCT01264822. Target conditions include Gastric Low-grade MALT Lymphoma With Helicobacter Pylori Positive.
Hype Score Breakdown
Clinical
5
Activity
2
Company
10
Novelty
2
Community
1
Clinical Trials (7)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01264822 | Pre-clinical | Completed |
| NCT01321567 | Pre-clinical | Completed |
| NCT00855361 | Phase 1 | Completed |
| NCT00747695 | Phase 1 | Completed |
| NCT01286194 | Pre-clinical | Completed |
| NCT00236184 | Phase 3 | Completed |
| NCT00132496 | Phase 2 | Completed |
Competing Products
20 competing products in Gastric Low-grade MALT Lymphoma With Helicobacter Pylori Positive